Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Takeda, Daiichi Sankyo, Astellas Lead Drug Firms' Corporate Image Ranking
December 20, 2010
- Kyorin Turns Down Sawai's Merger Proposal Again
December 20, 2010
- Otsuka: Aquaretic Agent Samsca for Volume Overload
December 20, 2010
- NPhA Reconfirms Opposition to Point Services
December 20, 2010
- PMDA's Reform Team Proposes Unification of PAFSC's PAC and Committees on Drugs
December 20, 2010
- C. Viehbacher Appointed as New PhRMA Chairman
December 20, 2010
- Sales of Ethical Drugs Down 3.4% in October: Crecon Report
December 20, 2010
- FPMAJ to Draft GL on Supply of Information on Drugs Used Off-Label
December 20, 2010
- New Drugs Make Up For Lipitor Patent Expiration: President Umeda of Pfizer
December 20, 2010
- Daiichi Sankyo Prioritizes 1st-in-Class Drugs in R&D: President Nakayama
December 20, 2010
- AZ's Ticagrelor Obtains EC Approval to Prevent Atherothrombotic Events in ACS
December 20, 2010
- Rifaximin to Drive ASKA's Business: President Yamaguchi
December 20, 2010
- BMS Applies for Additional Indication for SPRYCEL in Japan
December 20, 2010
- Sprycel Obtains EC Approval for a New Indication
December 20, 2010
- Novartis Recommends Rasilez for Use in First-Line Therapy
December 20, 2010
- Gov't Aims to Create Japanese Version of NIH
December 20, 2010
- FDA Advisory Committee Recommends Approval of Contrave for Obesity: Takeda
December 20, 2010
- MCHC Aims at Operating Profits of \120 Bil. for Healthcare Business in FY2015
December 20, 2010
- NCGM to Start IIT to Compare 3 Antidiabetic Drugs
December 20, 2010
- Pfizer to Develop Orphan Drugs Even if Profits Are Small: Mr Matsumori
December 20, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…